Genomic screening in children: BabyScreen+

Gene: TECRL

Green List (high evidence)

TECRL (trans-2,3-enoyl-CoA reductase like, Ensemblv90)
EnsemblGeneIds (GRCh38): ENSG00000205678
EnsemblGeneIds (GRCh37): ENSG00000205678
OMIM: 617242, ClinGen, DECIPHER
TECRL is in 1 panel

1 review

Lilian Rudd (Victorian Clinical Genetics Services)

Green List (high evidence)

Rated as 'strong actionability' for paediatric patients by ClinGen. Not on ACMG additional findings list.

The mean age of onset of symptoms (usually a syncopal episode) of CPVT is between age seven and twelve years; onset as late as the fourth decade of life has been reported. Nearly 60% of patients have at least one syncopal episode before age 40. If untreated, CPVT is highly lethal, as approximately 30% of genetically affected individuals experience at least one cardiac arrest and up to 80% one or more syncopal spells. In untreated patients, the 8-year fatal or near-fatal event rates of 25% have been reported. Sudden death may be the first manifestation of the disease.

Beta-blockers lacking intrinsic sympathomimetic activity are recommended as a first-line therapy in all patients with a clinical diagnosis of CPVT, including those with documented spontaneous, stress-induced VAs. Guidelines differ in their recommendations about utilizing beta-blocker therapy in phenotype negative individuals. Treatment with beta blockers is associated with a reduction in adverse cardiac events. However, variability in outcome with beta-blocker therapy is due to multiple factors, including dosing and compliance. In a study of 101 patients with CPVT (22 diagnosed clinically and 79 diagnosed molecularly), 81 were administered beta-blockers (57 symptomatic and 24 asymptomatic individuals). Estimated 4- and 8-year cardiac event rates were 8% and 27%, respectively in patients taking beta-blockers, and 33% and 58% in those not taking beta blockers (log-rank p=0.01). Corresponding statistics for fatal events were 1% and 11% with beta-blockers vs. 18% and 25% without (log-rank p=0.05). Event rates in asymptomatic patients with a positive genotype were similar to other patients. In multivariate models, absence of beta-blockers was an independent predictor of cardiac events (hazard ratio [HR], 5.48; 95% CI, 1.8 to 16.7, p=0.003) and of fatal events (HR, 5.54; 95% CI, 1.2 to 26.1, p=0.03). Of the 37 asymptomatic patients with a positive genotype, 9 (24%) had cardiac events.

In patients with CPVT and recurrent sustained VT or syncope, while receiving adequate or maximally tolerated beta blocker, treatment intensification with either combination medication therapy (e.g., beta blocker with flecainide), left cardiac sympathetic denervation, and/or an ICD is recommended.

Clinical penetrance ranges from 25 to 100%, with an average of 70 to 80%. Syncope appears to be the first symptom in more than half of the patients. When untreated, mortality from CPVT is high, reaching 30 to 50% by the age of 30 years.
Sources: Expert list
Created: 1 Sep 2025, 5:10 p.m.

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Ventricular tachycardia, catecholaminergic polymorphic, 3, MIM# 614021

Details

Mode of Inheritance
BIALLELIC, autosomal or pseudoautosomal
Sources
  • Expert Review Green
  • Expert list
Phenotypes
  • Ventricular tachycardia, catecholaminergic polymorphic, 3, MIM# 614021
OMIM
617242
ClinGen
TECRL
DECIPHER
TECRL
Clinvar variants
Variants in TECRL
Penetrance
None
Panels with this gene

History Filter Activity

Note: This information shows the history of the gene symbol, not the gene entity. Where the gene symbol for a gene has changed, this history may reference a different gene to the entry you are currently viewing.
1 Sep 2025, Gel status: 3

Entity classified by Genomics England curator

Lilian Rudd (Victorian Clinical Genetics Services)

Gene: tecrl has been classified as Green List (High Evidence).

1 Sep 2025, Gel status: 3

Entity classified by Genomics England curator

Lilian Rudd (Victorian Clinical Genetics Services)

Gene: tecrl has been classified as Green List (High Evidence).

1 Sep 2025, Gel status: 1

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Lilian Rudd (Victorian Clinical Genetics Services)

gene: TECRL was added gene: TECRL was added to Genomic screening in children: BabyScreen+. Sources: Expert list Mode of inheritance for gene: TECRL was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: TECRL were set to Ventricular tachycardia, catecholaminergic polymorphic, 3, MIM# 614021 Review for gene: TECRL was set to GREEN